Now Your Patient Can Be Unstoppable For 90 Days

Eversense is the only CGM system with a 90-day subcutaneous sensor – giving patients the longest wear time ever, along with unmatched convenience and accuracy.1,2,3

Why Eversense CGM?

sensor

90 days

The FDA-approved long-term CGM that lasts up to 90 days.

The advanced sensor technology and under the skin sensor help patients reach unprecedented levels of wear time, leading to improved clinical outcomes.

 

The only CGM with a powerful

98%
Wear Time
in clinical trials1,2

 



How We Outpace Other CGMS

Eversense

Up to 90-day sensor life

4 sensor changes per year

Only 4 ‘Day 1' warm-up periods

Sensor insertion by HCP

Transmitter is removable and provides unique on-body vibe alerts

Sensor stays put no matter what

Reduced irritation with gentle, silicone-based adhesive4

Traditional CGMs

Short sensor life of 7-14 days

26-52 sensor changes per year

26 - 52 ‘Day 1’ warm-up periods

Need to self-insert the sensor

Transmitter must remain adhered to skin for sensor duration

Percutaneous sensor can be dislodged during everyday activities

Acrylate-based adhesives can cause skin irritation

Ready to Get Started as a Provider?

Ready to prescribe Eversense CGM? Just fill out a simple form with a few details and we will contact you to answer questions and get you started.

 






  1. Christiansen MP, Klaff LJ, Brazg R, et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. doi:10.1089/dia.2017.0142.
  2. Christiansen MP, Klaff LJ, Bailey TS, Brazg R, Carlson G, Tweden KS. A Prospective Multicenter Evaluation of the Accuracy and Safety of an Implanted Continuous Glucose Sensor: The PRECISION Study. Diabetes Technology & Therapeutics. 2019;21(5):231-237. doi:10.1089/dia.2019.0020.
  3. Barnard KD, Kropff J, et al. Acceptability of Implantable Continuous Glucose Monitoring Sensor: Journal of Diabetes Science and Technology 2018, Vol. 12(3) 634 -638. DOI: 10.1177.
  4. Sanchez P, Ghosh-Dastidar S, Tweden K, Kaufman F. Real-World Data from the First US Commercial Users of an Implantable Continuous Glucose Sensor. Diabetes Technol Ther. Published online August 12, 2019, DOI:10.1089/dia.2019.0234.